Main Article Content

Abstract

  Diabetes mellitus is a major metabolic disorder whose prevalence is increasing daily. Medicinal plants have played an important role in the prevention and treatment of Diabetes mellitus.In ethnomedicinal practices, different parts of Mangifera indica are used for the treatment of diabetes. Mangifera indica extract showed presence of secondary metabolites such as tannins, xanthones, flavonoids, and terpenoids etc. These secondary metabolites are responsible for the anti-diabetic activity. In this study Mangifera indica chloroform peel extract was investigated for its promising anti-diabetic activity via an in vivo model. This experiment was conducted in a set of five with five groups of animals namely control group, toxicant group, standard group, Test I group and Test II group. To develop diabetes, Wistar rats were injected alloxan monohydrate intraperitoneally. Test I and Test II groups received a freshly prepared single dose of Mango peel chloroform extract in rice bran oil. All experimental groups received laboratory pallet feed diet and drinking water. Diabetic rats were treated for 21 days with an chloroform extract of mango peel orally daily at rates of 150 mg/kg b.w. and 200 mg/kg b.w. followed by histopathological evaluation of pancreas. It was found that Mangifera indica chloroform peel extract possessed highly significant activity (p > 0.001) at a concentrations of 150 mg/kg and 200 mg/ decreased the fasting blood levels in alloxan induced diabetic rats where as, standard metformin (200 mg/kg b.w.) showed significant (p<0.001) decrease in the fasting blood glucose levels.

Keywords

Mangifera Indica Anti-Diabetic Chloroform extract Metformin Alloxan monohydrate

Article Details

How to Cite
Zeeyauddin K, Sanjana G, Nagesh B, Vikas G, Mounika K, & Tulja Rani G. (2023). Invivo Evaluation Of Anti-Diabetic Activity Of Chloroform Peel Extract Of Mangifera Indica. International Journal of Research in Pharmacology & Pharmacotherapeutics, 12(4), 267-276. Retrieved from https://ijrpp.com/ijrpp/article/view/507

References

  1. 1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37;Suppl 1(Supplement_1):S81-90:S81-90. doi: 10.2337/dc14-S081, PMID 24357215.
  2. 2. Galtier F. Definition, epidemiology, risk factors. Diabetes Metab. 2010;36(6 Pt 2 Pt 2):628-51. doi: 10.1016/j.diabet.2010.11.014, PMID 21163426.
  3. 3. Yau M, Maclaren NK, Sperling MA. Etiology and pathogenesis of diabetes mellitus in children and adolescents. MDText.com; 2021.
  4. 4. DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitusin the United States, Pregnancy Risk Assessment Monitoring System (PRAMS). Prev Chronic Dis. 2007-
  5. 2010;11. 2014:(130415):E104. doi: 10.5888/pcd11.130415.
  6. 5. Md NK, Maclaren MD, Sperling MA. Etiology and Pathogenesis of Diabetes Mellitus in Children and Adolescents Mabel Yau. MD.
  7. 6. Ramachandran A. Know the signs and symptoms of diabetes. Indian J Med Res. 2014;140(5):579-81. PMID 25579136.
  8. 7. Scott A, Chambers D, Goyder E, O’Cathain A. Socioeconomic inequalities in mortality, morbidity and diabetes management for adults with type 1 diabetes: A. PLoS One. 2017;12(5):e0177210. doi: 10.1371/journal.pone.0177210, PMID 28489876.
  9. 8. Shuldiner AR, Yang R. Gong D-W. Resistin, obesity, and insulin resistance—theemerging role of the adipocyte as an endocrine organ. N Engl J Med.
  10. 9. Mazidi M, Toth PP, Banach M. C-reactive protein is associated with prevalence of the.
  11. 10. Niyitegeka J-MV, Bastidas AC, Newman RH, Taylor SS, Ongeri EM. Isoform-specificinteractions between meprin metalloproteases and the catalytic subunit of protein.
  12. 11. Brownrigg JRW, Schaper NC, Hinchliffe RJ. Diagnosis and assessment of peripheralarterial disease in the diabetic foot. Diabet Med. 2015;32(6):738-47. doi: 10.1111/dme.12749, PMID 25764390.
  13. 12. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia andcardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ.
  14. 13. Li L, Wan XH, Zhao GH. Meta-analysis of the risk of cataract in type 2 diabetes. BMC Ophthalmol. 2014;14(1):94. doi: 10.1186/1471-2415-14-94, PMID 25060855.
  15. 14. Agrawal RC. Pharmacological studies of Mangifera indica leaf extract. World J Bio Pharm. Health Sci. 2021;7(3):073-9. doi: 10.30574/wjbphs.2021.7.3.0100.
  16. 15. Pharmacological activities of mango (Mangifera indica): a review GM Masud Parvez. Pharmacological activities of mango (Mangifera indica): a review GM Masud Parvez.
  17. 16. Khandelwal KR. Practical pharmacognosy. Pragati Books; 2008.
  18. 17. Mistry J, Biswas M, Sarkar S, Ghosh S. Antidiabetic activity of mango peel extract and mangiferin in alloxan-induced diabetic rats. Futur J Pharm Sci. 2023;9(1). doi: 10.1186/s43094-023-00472-6.
  19. 18. Sudha Madhuri A, Mohanvelu R. Evaluation of antidiabetic activity of aqueous extract of Mangifera indica leaves in alloxan induced diabetic rats. Biomed Pharmacol J. 2017;10(2):1029-35. doi: 10.13005/bpj/1200.